论文部分内容阅读
病毒唑是一种非干扰素诱导的核苷酸类似物,具有广谱抗RNA和DNA病毒的作用。该药已试用于HIV、HBV及拉沙病毒感染患者。本文报道口服病毒唑治疗慢性丙型肝炎试验性研究的疗效及副反应。参试对象为10例肝活检证实的非甲非乙型肝炎,并且用ELISA检测多次抗-HCV阳性的患者,其中男性7例,女性3例,平均年龄40(23～54)岁。10例感染来源中4例为静注毒品成瘾者,5例曾经输血,1例原因不明。所有病例治疗前至少有12个月血清ALT升高。肝活检显示,有慢性活动性肝炎(CAH)及慢性迁延性肝炎(CPH)者各占50％。
Ribavirin is a non-interferon-induced nucleotide analog that has a broad spectrum of effects against RNA and DNA viruses. The drug has been tested for HIV, HBV and Lassa virus infection in patients. This article reports the efficacy and side effects of oral ribavirin in the experimental study of chronic hepatitis C. Participants were 10 non-A, non-B hepatitis patients confirmed by liver biopsy, and 7 were anti-HCV positive by ELISA, including 7 males and 3 females, with an average age of 40 (23-54) years. Of the 10 cases of infection, 4 were intravenous drug addicts, 5 had blood transfusions, and 1 was unexplained. In all cases, serum ALT increased at least 12 months before treatment. Liver biopsy showed 50% each of chronic active hepatitis (CAH) and chronic persistent hepatitis (CPH).